Indian vaccine market to reach valuation of Rs 252 bn by 2025: Jitendra Singh

Singh said that the world is now increasingly realising India’s superlative capacities in preventive healthcare and we are now in the process of developing several other vaccines in the series. Recently after the first DNA vaccine, the first nasal vaccine has also been successfully manufactured and another vaccine related to Human Papillomavirus (HPV) which has helped in the prevention of cervical cancer has also been developed.